Education
About Us
Working with TipRanks
Follow Us
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
TARS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$35.34 - $70.78
Previous CloseN/A
Volume127.14K
Average Volume (3M)730.59K
Market Cap
$2.96B
Enterprise Value$1.41B
Total Cash (Recent Filing)$381.14M
Total Debt (Recent Filing)$72.45M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Nov 05, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding42,214,108
10 Day Avg. Volume709,577
30 Day Avg. Volume730,591
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)9.27
Price to Sales (P/S)11.38
P/FCF Ratio-24.61
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue4.76
Enterprise Value/Gross Profit5.10
Enterprise Value/Ebitda-16.56
Forecast
1Y Price Target
$74.17Price Target Upside5.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Market PenetrationThe prescriber base has expanded beyond the initial target with now more than 20,000 prescribing Xdemvy, providing a strong foundation of script volume moving forward.
Product AdoptionManagement noted the success it has seen in driving prescribing across patient segments, with 80% of its target ECPs prescribing Xdemvy across key patient segments, double the amount that had prescribed across segments on its fourth-quarter call.
Revenue GrowthXDEMVY has reached quarterly net product sales surpassing $100M per quarter, as the first and only FDA approved therapy to treat Demodex blepharitis.
Bears Say
Investor SentimentShort interest is relatively high at 21.5% of the float, which may indicate that some investors are betting against the stock.
Tarsus Pharmaceuticals News
TARS FAQ
What was Tarsus Pharmaceuticals’s price range in the past 12 months?
Tarsus Pharmaceuticals lowest stock price was $35.34 and its highest was $70.78 in the past 12 months.
What is Tarsus Pharmaceuticals’s market cap?
Tarsus Pharmaceuticals’s market cap is $2.96B.
When is Tarsus Pharmaceuticals’s upcoming earnings report date?
Tarsus Pharmaceuticals’s upcoming earnings report date is Nov 05, 2025 which is in 23 days.
How were Tarsus Pharmaceuticals’s earnings last quarter?
Tarsus Pharmaceuticals released its earnings results on Aug 06, 2025. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.379 by -$0.101.
Is Tarsus Pharmaceuticals overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals’s price is currently Undervalued.
Does Tarsus Pharmaceuticals pay dividends?
Tarsus Pharmaceuticals does not currently pay dividends.
What is Tarsus Pharmaceuticals’s EPS estimate?
Tarsus Pharmaceuticals’s EPS estimate is -0.35.
How many shares outstanding does Tarsus Pharmaceuticals have?
Tarsus Pharmaceuticals has 42,214,108 shares outstanding.
What happened to Tarsus Pharmaceuticals’s price movement after its last earnings report?
Tarsus Pharmaceuticals reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.379. Following the earnings report the stock price went up 15.154%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals?
Currently, no hedge funds are holding shares in TARS
Tarsus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.17 (5.75% Upside)
$74.17 (5.75% Upside)
Blogger Sentiment
Bullish
TARS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 162.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.57%
12-Months-Change
Fundamentals
Return on Equity
-31.46%
Trailing 12-Months
Asset Growth
31.35%
Trailing 12-Months
Company Description
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
TARS Company Deck
TARS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong sales performance and successful marketing efforts, indicating significant growth and expansion potential for XDEMVY. While there are challenges in managing expenses and gross-to-net improvements, the positive aspects, including financial stability and strategic pipeline development, outweigh the negatives.View all TARS earnings summariesTARS Stock 12 Month Forecast
Average Price Target
$74.17
▲(5.75% Upside)
Technical Analysis
Denali Therapeutics
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
3.25% Insiders
21.27% Mutual Funds
53.87% Other Institutional Investors
9.09% Public Companies and
Individual Investors